新型冠状病毒肺炎疫情下治疗药物监测实验室气溶胶产生风险及应对

Risk of Aerosol Transmission in Therapeutic Drug Monitoring Laboratory and Its Countermeasures During the Coronavirus Disease 2019 Epidemic

目的降低新型冠状病毒肺炎(COVID-19)疫情下治疗药物监测(TDM)实验室的气溶胶传播风险。方法总结气溶胶的定义、分类、产生原因,从操作控制及个人防护等方面进行分析。结果气溶胶种类较多,且不同粒径传播特点也不同;TDM实验室样本接收、处理过程中若操作不慎均可能产生气溶胶,需从TDM实验室气溶胶的控制、工作环境的防护、实验人员的个人防护等方面入手降低其传播风险。结论TDM相关工作人员应高度重视COVID-19疫情防控和职业暴露保护。TDM实验室血液样本前处理步骤中涉及高速离心、开盖、振荡混匀、移液、超声等易产生生物气溶胶的操作时,需采取有效措施防范。

Objective To reduce the risk of aerosol transmission in the therapeutic drug monitoring(TDM)laboratory during the coronavirus disease 2019(COVID-19)epidemic.Methods The definition,classification and causes of aerosol were summarized,and the risk of aerosol transmission was analyzed from the operation control and personal protection.Results There are many kinds of aerosols,and the transmission characteristics of different particle sizes are different.Aerosol may be produced if the operation is not careful in the process of sample receiving and processing in the TDM laboratory.It is necessary to reduce the transmission risk from the aspects of aerosol control in the TDM laboratory,protection of working environment,personal protection of laboratory personnel,etc..Conclusion The relevant TDM staff should attach great importance to the prevention and control of the COVID-19 epidemic and the protection of occupational exposure.In the process of blood sample pretreatment in the TDM laboratory,when it involves high-speed centrifugation,cover opening,shaking and mixing,liquid transfer,ultrasound and other operations that are prone to produce biological aerosols,effective measures should be taken to prevent them.